CRISTINA MARGARITA SAIZ RODRIGUEZ M.D.
Prescription History 1023219219
Obstetrics & Gynecology - Urogynecology and Reconstructive Pelvic Surgery in Oradell, NJ

NPI Status: Active since May 29, 2007

Contact Information

680 KINDERKAMACK RD
SUITE 204
ORADELL, NJ
ZIP 07649
Phone: (201) 391-5443

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for CRISTINA MARGARITA SAIZ RODRIGUEZ M.D., an active Urogynecology and Reconstructive Pelvic Surgery specialist practicing in Oradell, NJ. Our medical registry currently tracks 9 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 816 documented patient claims. Among these therapy options, the most frequently utilized medication is Estradiol, which accounts for 442 claims alone.


Cefuroxime

Generic Formulation: Cefuroxime AxetilSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 18
30-Day Fills 18.0
Days Supply 108
NJ State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills33.5
Peer Average Days Supply289
Conservative Utilization

This provider writes prescriptions for this formulation 43.8% less frequently than the standard regional baseline metric for practitioners inside NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $250.56 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.92

State Avg Cost Per Claim

$24.40

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cephalosporin antibiotic.

Therapeutic Applications

Cefuroxime is used to treat a wide variety of bacterial infections. This medication is known as a cephalosporin antibiotic. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Estradiol

Generic Formulation: EstradiolSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 442
30-Day Fills 1,142.0
Days Supply 34,210
NJ State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills95.6
Peer Average Days Supply2,848
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 1,005.0% higher than the standard regional baseline profile for NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $42,551.63 across this reporting matrix range.

Provider Avg Cost Per Claim

$96.27

State Avg Cost Per Claim

$121.82

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Therapeutic Applications

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

Estring

Generic Formulation: EstradiolSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 27
30-Day Fills 81.0
Days Supply 2,430
NJ State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills58.3
Peer Average Days Supply1,748
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 42.1% more claims than the standard regional baseline profile for NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $13,644.14 across this reporting matrix range.

Provider Avg Cost Per Claim

$505.34

State Avg Cost Per Claim

$519.88

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Therapeutic Applications

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

Gemtesa

Generic Formulation: VibegronSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 31
30-Day Fills 56.0
Days Supply 1,639
NJ State Average Benchmarks
Peer Average Claims39.0
Peer Average 30-Day Fills62.4
Peer Average Days Supply1,841
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $25,717.68 across this reporting matrix range.

Provider Avg Cost Per Claim

$829.60

State Avg Cost Per Claim

$719.90

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat overactive bladder. Overactive bladder is a problem with how your bladder stores urine that causes a sudden urge to urinate. The urge may be hard to control, and overactive bladder symptoms may include frequent urination, strong sudden urges to urinate, or involuntary loss of urine (incontinence). Vibegron works by relaxing a certain bladder muscle (detrusor), which helps the bladder hold more urine and lessens symptoms of overactive bladder.

Myrbetriq

Generic Formulation: MirabegronSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 186
30-Day Fills 445.0
Days Supply 13,327
NJ State Average Benchmarks
Peer Average Claims53.0
Peer Average 30-Day Fills88.7
Peer Average Days Supply2,570
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 250.9% higher than the standard regional baseline profile for NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $199,666.97 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,073.48

State Avg Cost Per Claim

$707.80

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain bladder problems (overactive bladder, neurogenic detrusor overactivity). Overactive bladder is a problem with how your bladder stores urine. Neurogenic detrusor overactivity is a bladder control condition caused by brain, spinal cord, or nerve problems. Symptoms of these conditions may include frequent urination, strong sudden urges to urinate that are hard to control, or involuntary loss of urine (incontinence). Mirabegron works by relaxing a certain bladder muscle (detrusor), which helps the bladder hold more urine and lessens symptoms of overactive bladder and neurogenic detrusor overactivity.

Nitrofurantoin Mono-Macro

Generic Formulation: Nitrofurantoin Monohyd/M-CrystSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 65
30-Day Fills 65.0
Days Supply 338
NJ State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills28.2
Peer Average Days Supply242
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 140.7% higher than the standard regional baseline profile for NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $883.48 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.59

State Avg Cost Per Claim

$22.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is an antibiotic used to treat bladder infections (acute cystitis). It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections. This medication should not be used in infants younger than 1 month old (see also Precautions section). This drug should not be used to treat infections outside the bladder (including kidney infections such as pyelonephritis or perinephric abscesses).

Oxycodone-Acetaminophen

Generic Formulation: Oxycodone Hcl/AcetaminophenSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 23
NJ State Average Benchmarks
Peer Average Claims56.0
Peer Average 30-Day Fills56.9
Peer Average Days Supply1,160
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 80.4% less volume than the regional standard for practitioners inside NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $21.69 across this reporting matrix range.

Provider Avg Cost Per Claim

$1.97

State Avg Cost Per Claim

$23.05

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination medication is used to help relieve moderate to severe pain. It contains an opioid pain reliever (oxycodone) and a non-opioid pain reliever (acetaminophen). Oxycodone works in the brain to change how your body feels and responds to pain. Acetaminophen can also reduce a fever.

Premarin

Generic Formulation: Estrogens, ConjugatedSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 18
30-Day Fills 38.3
Days Supply 1,147
NJ State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills47.9
Peer Average Days Supply1,419
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $8,412.60 across this reporting matrix range.

Provider Avg Cost Per Claim

$467.37

State Avg Cost Per Claim

$429.13

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation containing a mixture of water-soluble, conjugated estrogens derived wholly or in part from URINE of pregnant mares or synthetically from ESTRONE and EQUILIN. It contains a sodium-salt mixture of estrone sulfate (52-62%) and equilin sulfate (22-30%) with a total of the two between 80-88%. Other concomitant conjugates include 17-alpha-dihydroequilin, 17-alpha-estradiol, and 17-beta-dihydroequilin. The potency of the preparation is expressed in terms of an equivalent quantity of sodium estrone sulfate.

Therapeutic Applications

This medication is a female hormone. It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment. Certain estrogen products may also be used by men and women to treat cancers (certain types of prostate cancer, breast cancer that has spread to other parts of the body) and by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure).

Yuvafem

Generic Formulation: EstradiolSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 18
30-Day Fills 51.2
Days Supply 1,536
NJ State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills48.0
Peer Average Days Supply1,411
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,436.47 across this reporting matrix range.

Provider Avg Cost Per Claim

$246.47

State Avg Cost Per Claim

$200.44

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Therapeutic Applications

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like CRISTINA MARGARITA SAIZ RODRIGUEZ M.D. provides transparency into local medical care patterns within Oradell, NJ.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Urogynecology and Reconstructive Pelvic Surgery** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.